FORA Capital LLC Sells 24,514 Shares of TransMedics Group, Inc. $TMDX

Key Points

• FORA Capital LLC significantly reduced its stake in TransMedics Group by 85.5%, now holding only 4,161 shares after selling 24,514 shares in the first quarter, valued at approximately $280,000.
• Several institutional investors, including Braidwell LP and Dimensional Fund Advisors, made substantial increases to their holdings in TransMedics Group, showcasing growing institutional interest in the company.
• Analysts have revised their ratings and price targets for TransMedics Group, with a consensus rating of "Moderate Buy" and an average price target set at $123.00, following a strong quarterly earnings report that exceeded expectations.

FORA Capital LLC decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 85.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,161 shares of the company's stock after selling 24,514 shares during the period. FORA Capital LLC's holdings in TransMedics Group were worth $280,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in TMDX. Dimensional Fund Advisors LP boosted its holdings in TransMedics Group by 1,565.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after acquiring an additional 253,624 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in TransMedics Group by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 19,640 shares of the company's stock valued at $1,225,000 after acquiring an additional 1,116 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in TransMedics Group by 1,602.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock valued at $272,000 after acquiring an additional 4,103 shares during the last quarter. State of Tennessee Department of Treasury bought a new position in TransMedics Group in the fourth quarter valued at about $830,000. Finally, Stifel Financial Corp boosted its holdings in TransMedics Group by 20.8% in the fourth quarter. Stifel Financial Corp now owns 8,968 shares of the company's stock valued at $559,000 after acquiring an additional 1,544 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Price Performance

NASDAQ TMDX traded down $1.76 during midday trading on Friday, hitting $114.96. The company had a trading volume of 665,581 shares, compared to its average volume of 942,848. The company has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.18. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a 50-day moving average price of $120.24 and a 200-day moving average price of $103.29. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $172.78.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same quarter in the previous year, the firm earned $0.35 EPS. TransMedics Group's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMDX. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Wall Street Zen lowered TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $123.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.